Written by Muhammad Johar Altaf Khan
MSc Chemistry | MBA | QC Manager, Pharmaceutical Industry
Medically Reviewed by Dr. Ayesha
MBBS | Family Physician
Pharmaceutical & Medication Reviewed by Dr. Ayesha Batool
PharmD
Scientific & Research Reviewed by Dr. Rehan Ahmed Siddiqui
Scientific & Research Reviewer
Last Updated: August 2026
Mounjaro vs Ozempic Side Effects: What’s the Difference?
Side effects are usually the easiest part of a Mounjaro versus Ozempic comparison to find. Nausea, vomiting, diarrhea, constipation—you’ll see the same symptoms listed again and again.
What those lists often fail to explain is why these symptoms happen in the first place, and whether the two medicines really affect people in the same way.
They don’t.
Mounjaro contains tirzepatide, while Ozempic contains semaglutide. Tirzepatide acts on both GIP and GLP-1 receptors, whereas semaglutide acts through the GLP-1 receptor. That difference is more than a technical detail. It helps explain some of the changes people notice in appetite, fullness, digestion, and gastrointestinal symptoms during treatment.
There is another point that is easy to miss. A side-effect percentage from a clinical trial tells us what happened in a study population; it does not predict exactly what will happen to you. Dose, dose escalation, other medicines, underlying health, and individual response can all change the experience.
So rather than simply asking which medicine has the longer list of side effects, it makes more sense to look at what is happening underneath that list.
In this comparison, we’ll put the pharmacology, pharmaceutical perspective, clinical evidence, and important safety warnings together to see where Mounjaro and Ozempic genuinely differ—and where they don’t.
Mounjaro and Ozempic Are Not the Same Medicine
It is easy to think of Mounjaro and Ozempic as two versions of the same treatment because they are both injectable medicines used in diabetes care and, in different approved contexts, weight management.
Pharmacologically, however, they are different.
Mounjaro contains tirzepatide. Tirzepatide activates two hormone receptors: GIP and GLP-1.
Ozempic contains semaglutide. Semaglutide acts primarily through the GLP-1 receptor.
Both pathways influence blood glucose regulation and appetite. They also affect gastrointestinal function, which is one reason stomach-related symptoms appear so frequently with both medicines.
That distinction matters when comparing side effects. You cannot always look at two drugs with similar clinical uses and assume that their effects on the body will be identical.
Why Do Mounjaro and Ozempic Cause Stomach Problems?
The stomach is often where people notice these medicines first.
Both medicines act on incretin pathways involved in glucose regulation, appetite, and gastrointestinal function. They can slow gastric emptying and increase the feeling of fullness after eating.
That can be helpful when the goal is to reduce food intake.
It can also be uncomfortable.
A meal that once felt normal may suddenly leave you feeling full much earlier than expected. Some people experience nausea. Others notice bloating, constipation, diarrhea, or occasional vomiting.
So there is an important connection here:
One of the physiological effects that can help these medicines reduce food intake can also contribute to some of their most common side effects.
That does not mean every stomach symptom is harmless, and it does not mean the medicines are “damaging” the stomach. It means the treatment is changing normal gastrointestinal signalling, and some people feel that change more strongly than others.
Mounjaro vs Ozempic: Common Side Effects
The two medicines have considerable overlap in their gastrointestinal side-effect profiles.
| Side Effect | Mounjaro | Ozempic |
|---|---|---|
| Nausea | Common | Common |
| Vomiting | Common | Common |
| Diarrhea | Common | Common |
| Constipation | Common | Common |
| Abdominal discomfort or pain | Can occur | Can occur |
| Decreased appetite | Common | Common |
| Gastrointestinal reactions | Possible | Possible |
The exact frequency varies according to dose, study population, treatment duration, and study design.
That last point matters more than it may seem.
A percentage taken from one clinical trial should not automatically be placed beside a percentage from a completely different trial and treated as a perfect head-to-head comparison.
Why Side Effects Can Become More Noticeable After a Dose Increase
This is something patients often notice in real life.
A person may feel fine on one dose, then develop nausea or other gastrointestinal symptoms after moving to the next dose.
There is a reason the doses are generally increased gradually rather than starting treatment at the full maintenance dose.
The body needs time to adjust.
Clinical studies of both tirzepatide and semaglutide have shown that gastrointestinal adverse events are particularly common during periods of dose escalation. For many patients, these symptoms become less troublesome as treatment continues.
But “often improves” does not mean “always improves.”
Someone who continues to experience significant nausea, repeated vomiting, severe abdominal pain, or other concerning symptoms should not simply assume that the body will eventually get used to it.
What Happens When Researchers Compare Them Directly?
This is where the evidence becomes much more useful.
The SURPASS-2 trial directly compared tirzepatide with semaglutide in people with type 2 diabetes.
Because both medicines were evaluated within the same study, the comparison is more informative than simply taking side-effect numbers from unrelated trials.
Nausea occurred in approximately:
- 17–22% of people receiving tirzepatide
- 18% of people receiving semaglutide
Diarrhea occurred in approximately:
- 13–16% with tirzepatide
- 12% with semaglutide
Vomiting occurred in approximately:
- 6–10% with tirzepatide
- 8% with semaglutide
Most gastrointestinal adverse events were mild to moderate.
Notice something about those numbers: they overlap considerably.
That makes it difficult to support a simple statement such as “Mounjaro causes more nausea” or “Ozempic is easier on the stomach.”
The evidence is more nuanced than that.
Why You Should Be Careful With Side-Effect Percentages
This is one of the easiest mistakes to make when reading medical information online.
Suppose one website says nausea occurred in 18% of patients taking one medicine and another says it occurred in 22% with another.
It is tempting to conclude that the second medicine is worse.
But before making that comparison, you would need to know whether the two studies had similar:
- patient populations
- doses
- treatment durations
- dose-escalation schedules
- definitions of adverse events
- methods of collecting and reporting symptoms
They may not.
This is why head-to-head trials are particularly valuable.
The number itself is only part of the story. You also need to know how that number was produced.
What Did SURMOUNT-5 Find?
The SURMOUNT-5 trial provides another useful comparison.
It studied tirzepatide and semaglutide in adults with obesity who did not have diabetes.
The trial included 751 participants and followed them for 72 weeks.
Tirzepatide produced greater average weight loss than semaglutide in the study.
But greater weight loss does not automatically mean fewer side effects—or better tolerability for every patient.
Gastrointestinal adverse events were the most frequently reported adverse events with both treatments. Most were mild to moderate, and many occurred during the dose-escalation period.
That distinction is important.
A medicine can produce greater average weight loss in a clinical trial while still causing gastrointestinal symptoms in some of the people taking it.
Effectiveness and tolerability are related, but they are not the same thing.
What About People Who Lose Weight Quickly?
A 2026 post-hoc analysis of SURMOUNT-5 looked at people who had lost at least 15% of their body weight by Week 24.
These rapid responders had numerically more gastrointestinal and hepatobiliary adverse events than non-rapid responders.
However, this was a post-hoc finding and does not prove that faster weight loss caused those events. The researchers also found no apparent trend linking early weight loss with hepatobiliary adverse events.
That distinction matters.
A pattern in a study can be worth investigating without being proof of cause and effect.
So, Which One Causes More Nausea?
There is no reliable one-word answer.
Both Mounjaro and Ozempic can cause nausea.
Both can cause vomiting.
Both can affect bowel habits.
And individual tolerance can vary considerably.
One person may struggle with nausea after starting semaglutide but tolerate tirzepatide reasonably well. Another person may have the opposite experience.
That is why I would be cautious about statements that label one medicine as universally “easier on the stomach.”
Clinical trial averages are useful for understanding populations.
They are not a prediction of exactly what will happen to one individual.
What Pharmaceutical Quality Can—and Cannot—Tell You
There is another distinction that is often missing from online discussions about medication side effects.
From a pharmaceutical quality-control perspective, medicines are expected to meet established requirements for things such as identity, strength, purity, quality, and consistency.
Those controls are fundamental.
But they cannot make every patient respond to a medicine in exactly the same way.
A medicine can meet its specifications and still cause nausea in one person while causing very little discomfort in another.
That is not automatically a manufacturing-quality problem.
It is the difference between product consistency and biological variability.
In simple terms:
Quality control asks whether the medicine is what it is supposed to be.
Clinical medicine also has to ask:
How will this particular person’s body respond to it?
Those are two different questions.
When Is a Side Effect More Than Just a Side Effect?
Not every episode of nausea is an emergency.
But some symptoms deserve more attention than others.
Both medicines have important safety warnings involving conditions such as:
- pancreatitis
- gallbladder disease
- dehydration and kidney problems
- severe gastrointestinal reactions
- hypoglycemia when combined with certain glucose-lowering medicines
- serious hypersensitivity reactions
- thyroid C-cell tumors
Severe or persistent abdominal pain
Significant abdominal pain should not automatically be dismissed as an ordinary medication side effect.
Pancreatitis is an important safety concern associated with these medicines.
Repeated vomiting or diarrhea
Persistent fluid loss can cause dehydration and may contribute to kidney problems, particularly in vulnerable patients.
Symptoms that are severe or getting worse
If a symptom is persistent, severe, or unusual for you, speak with a healthcare professional rather than trying to determine the cause from an online side-effect list.
What About the Thyroid Cancer Warning?
This is another area where headlines can make the issue sound simpler than it actually is.
Both Mounjaro and Ozempic carry important warnings concerning thyroid C-cell tumors.
The concern comes from findings in rodents, and the prescribing information states that it is unknown whether this finding applies to humans.
These medicines are contraindicated in people with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
That is very different from simply saying:
“Mounjaro and Ozempic cause thyroid cancer.”
The evidence does not justify that blanket statement.
When discussing medication risks, the exact wording matters.
Don’t Change the Dose on Your Own
Side effects can make people look for alternatives online.
You may come across suggestions about taking smaller doses, changing injection schedules, or splitting doses.
That does not mean those approaches are appropriate or supported for your particular treatment.
If a prescribed dose is difficult to tolerate, the safer approach is to discuss the problem with the healthcare professional managing your treatment.
Dose selection and dose escalation are part of the medication plan. They are not simply scheduling decisions that should be adjusted based on someone else’s experience online.
Other Medicines Matter Too
Mounjaro or Ozempic may not be the only medicines a person is taking.
For example, the risk of hypoglycemia can become more important when these medicines are used with certain other glucose-lowering medications.
That is why a medication review matters.
Your healthcare professional should know about your prescription medicines, over-the-counter products, and supplements.
Helpful Medication Management Tool
If you take medicines or supplements on a regular schedule, a weekly pill organizer can help keep your daily medications organized and make your routine easier to follow.
Ezy Dose Weekly 7-Day AM/PM Pill Organizer → Check it on Amazon
As an Amazon Associate, MedicalBluff earns from qualifying purchases.
Sometimes the right question isn’t:
“Is Mounjaro causing this?”
It may be:
“What else could be contributing to this patient’s symptoms?”
That broader view is often much more useful.
Which One Is Better for You?
There isn’t a universal answer.
The choice between Mounjaro and Ozempic may depend on factors such as:
- why the medicine is being prescribed
- your treatment goals
- your medical history
- other medicines you take
- previous medication reactions
- how you respond during dose escalation
- contraindications and safety considerations
The SURMOUNT-5 trial found greater average weight loss with tirzepatide than semaglutide in the population studied.
That is meaningful evidence.
But it does not mean every person will lose more weight with tirzepatide, or that every person will tolerate it better.
Clinical trials tell us what happened on average.
Treatment decisions still have to account for the individual patient.
The Difference Between a Side-Effect List and Understanding the Medicine
This is probably the most important point in the whole comparison.
A drug is not simply a list of possible side effects.
There is a molecule behind it.
There are receptor interactions.
There is dose and exposure.
There are pharmacokinetic and pharmacodynamic effects.
There is pharmaceutical manufacturing and quality control.
And then there is the patient.
The patient is not a standardized laboratory sample.
That is why two people can take the same medicine at the same dose and describe completely different experiences.
One person may say:
“The first few weeks were rough, but it settled down.”
Another may say:
“I couldn’t tolerate the next dose.”
Both experiences can be genuine.
Neither one, by itself, proves that the medicine is good or bad.
Mounjaro vs Ozempic: The Practical Takeaway
Mounjaro and Ozempic have substantial overlap in their side-effect profiles, particularly when it comes to gastrointestinal symptoms.
But they are not the same drug.
Mounjaro → tirzepatide → GIP + GLP-1
Ozempic → semaglutide → GLP-1
Both can cause nausea, vomiting, diarrhea, constipation, and other gastrointestinal symptoms. These problems are often most noticeable during dose escalation and may become less troublesome with continued treatment, although that is not guaranteed.
The clinical evidence also does not give us a simple rule that one medicine is always easier to tolerate.
And there is one broader pharmaceutical point worth remembering:
A consistent medicine does not produce a perfectly consistent human response.
Quality control can help ensure that a medicine has the required identity, strength, purity, and quality.
It cannot predict exactly how your body will respond.
So if you’re deciding between Mounjaro and Ozempic, don’t base the decision on one side-effect percentage or someone else’s experience.
Look at the evidence.
Look at the medicine.
Look at the dose.
And look at the person taking it.
That is where a meaningful comparison begins.
Frequently Asked Questions
Is Mounjaro worse than Ozempic for side effects?
Not necessarily. Both medicines can cause gastrointestinal side effects, and individual tolerance varies considerably.
Which causes more nausea, Mounjaro or Ozempic?
Both can cause nausea. Direct comparative evidence shows considerable overlap, so there is no reliable rule that one will always cause more nausea.
Why do Mounjaro and Ozempic cause stomach problems?
Both medicines influence signalling involved in appetite and gastrointestinal function. Changes in gastric emptying and digestion can contribute to nausea, fullness, vomiting, and changes in bowel habits.
Do Mounjaro and Ozempic side effects get better?
For many patients, gastrointestinal symptoms are most noticeable during dose escalation and may become less troublesome over time. Persistent or severe symptoms should still be discussed with a healthcare professional.
Is Mounjaro chemically the same as Ozempic?
No. Mounjaro contains tirzepatide, which acts on GIP and GLP-1 receptors. Ozempic contains semaglutide, which acts through the GLP-1 receptor.
Does Mounjaro cause more weight loss than Ozempic?
In the 72-week SURMOUNT-5 trial, tirzepatide produced greater average weight loss than semaglutide in adults with obesity who did not have diabetes.
Can I change my Ozempic dose if I’m having side effects?
Do not change the dose or dosing schedule on your own. Talk with the healthcare professional managing your treatment.
Bottom Line
Mounjaro and Ozempic are similar in some important ways, but they are not interchangeable versions of the same medicine.
Both can cause gastrointestinal side effects. Both have important safety warnings. And neither medicine will produce exactly the same experience in every patient.
The underlying pharmacology is different: tirzepatide acts on GIP and GLP-1 receptors, while semaglutide acts through the GLP-1 receptor.
From there, dose, dose escalation, other medicines, underlying health, and individual biology all influence what a patient actually experiences.
And perhaps the simplest way to remember the whole comparison is this:
The medicine can be consistent. The response doesn’t have to be.
That is why the best Mounjaro-versus-Ozempic decision is not based on which side-effect list looks shorter. It is based on the evidence, the treatment goal, the patient’s circumstances, and the clinical judgment of the healthcare professional prescribing it.
References
- U.S. Food and Drug Administration. Mounjaro (tirzepatide) Prescribing Information. 2026.
- Frías JP, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
- Aronne LJ, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. New England Journal of Medicine. 2025.
- Aronne LJ, et al. Relationship of Early Rapid Weight Loss to Efficacy and Safety of Tirzepatide and Semaglutide for Obesity: SURMOUNT-5 Post Hoc Analysis. 2026.
